Clinical Trial Update: Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction [Phase 3]

View source ↗

Summary

Phase 3 trial update on using Bacille Calmette-Guérin (BCG) vaccine in infants to reduce allergy and infections; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Diseases
• Atopic Dermatitis
• Respiratory Tract Infection

Drugs mentioned

• BCG vaccine (Bacillus Calmette-Guérin)

Snippet

Sponsor: Murdoch Childrens Research Institute | Conditions: Allergy, Eczema | Phase 3 | Status: COMPLETED